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Donor chimerism after allogeneic stem cell transplantation (allo-SCT) is commonly used to predict overall
survival (OS) and disease-free survival (DFS). Because chimerism is observed at 1 or more times after allo-SCT
and not at baseline, if chimerism is in fact associated with OS or DFS, then the occurrence of either disease
progression or death informatively censors (terminates) the observed chimerism process. This violates the
assumptions underlying standard statistical regression methods for survival analysis, which may lead to
biased conclusions. To assess the association between the longitudinal posteallo-SCT donor chimerism
process and OS or DFS, we analyzed data from 195 patients with acute myelogenous leukemia (n ¼ 157) or
myelodysplastic syndrome (n ¼ 38) who achieved complete remission after allo-SCT following a reduced-
toxicity conditioning regimen of ﬂudarabine/intravenous busulfan. Median follow-up was 31 months
(range, 1.1 to 105 months). Fitted joint longitudinal-survival time models showed that a binary indicator of
complete (100%) donor chimerism and increasing percent of donor T cells were signiﬁcantly associated with
longer OS, whereas decreasing percent of donor T cells was highly signiﬁcantly associated with shorter OS.
Our analyses illustrate the usefulness of modeling repeated posteallo-SCT chimerism measurements as in-
dividual longitudinal processes jointly with OS and DFS to estimate their relationships.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic stem cell transplantation (allo-SCT) is an
effective and potentially curative treatment modality for
patients with acute myeloid leukemia (AML) and myelo-
dysplastic syndrome (MDS). The 2 primary goals of allo-SCT
are to reestablish hematopoiesis in the patient after receiving
a myeloablative preparative regimen and to mount a graft-
versus-leukemia immune response to eliminate residual
leukemia. Numerous prognostic factors currently are fol-
lowed posteallo-SCT to detect disease relapse in patients
who achieve complete remission (CR), including hematologic
parameters and cytogenetic and molecular mutations in the
bone marrow. Early detection and treatment of minimal re-
sidual disease before overt hematologic relapse after allo-
SCT are associated with better outcomes, because it often
leads to implementation of adaptive therapeutic decisions,
such as decreasing immunosuppression, donor lymphocyte
infusions, or administration of a chemotherapeutic agent,
such as azacitidine, to consolidate and maintain remission
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14.04.003Chimerism (percent of donor-derived blood cells) after
allo-SCT also has been used prognostically for disease relapse
[2,4-8]. This requires measuring chimerism at 1 or more time
points after allo-SCT. The presence of cells of host origin after
allo-SCT in the absence of an overt diagnosis of residual AML
may indicate inadequate myeloablation or persistence of
host-derived malignant cell clones, which ultimately can
lead to clinical disease recurrence. Consequently, a high
percentage of patient cells after allo-SCT may predict
impending disease relapse.
Assessing a possible association between chimerism and
disease-free survival (DFS) or overall survival (OS) is not
entirely straightforward because chimerism is measured
longitudinally at 1 or more times after allo-SCT; conse-
quently, chimerism is a treatment outcome process and not
simply a baseline covariate. If the chimerism process is
associated with DFS or OS, then the direction and rate of
change of the chimerism process, speciﬁcally the slope of the
chimerism timeline, may be the key aspect that is predictive
of OS or DFS. Standard statistical survival time regression
methods, such as a Cox model analysis, cannot reveal such
relationships because they require covariates to be measured
only at baseline (allo-SCT) or, alternatively, require a land-
mark analysis [9] wherein time is measured from a single
chimerismmeasurement. Another problem is that relapse or
death may be an informative censoring variable for the
longitudinal chimerism process, which leads to biasedTransplantation.
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tion of the longitudinal process of successive chimerism
measurements and the time of the terminating event
(relapse or death) [10-12]. The chimerism process, DFS, or OS
also may be inﬂuenced by other factors recorded at the time
of allo-SCT, including the intensity of the preparative
regimen, T cell composition of the graft [13,14], chimerism
lineage (lymphoid versus myeloid), sample source (bone
marrow versus peripheral blood), timing of the chimerism
evaluations after allo-SCT, and method used to measure
chimerism.
Studies examining the predictive ability of percent
chimerism have produced conﬂicting results. Although some
have shown that early chimerism detection can be used to
predict relapse in pediatric patients with acute lympho-
blastic leukemia (ALL) and AML [6,7,15], other studies have
concluded that the prognostic value of chimerism is limited
or not associated with disease relapse in patients, speciﬁcally
in patients with ALL whose chimerism status was evaluated
80 days after allo-SCT [16,17]. Despite these conﬂicting con-
clusions, there remains a need for a reliable prognostic var-
iable for disease relapse after allo-SCT. A report by the
National Cancer Institute on the prevention and treatment of
relapse after allo-SCT highlighted the need for surrogate
markers and proposed several speciﬁc objectives concerning
the predictive value of early detection methods such as
percent chimerism [18]. The workshop highlights the critical
role of determining the frequency for monitoring minimal
residual disease and chimerism after allo-SCT and assess-
ment of the efﬁcacy of interventional strategies based on
changes in minimal residual disease and/or chimerism to
prevent overt clinical relapse [18].
Because the value of chimerism at a single time point
after allo-SCT may be misleading as it ignores the path (di-
rection and slope) of the chimerism process over time, we
sought to determine whether longitudinal chimerism mea-
surements can be used to more accurately predict relapse in
patients after allo-SCT. Here, we describe a retrospective
analysis investigating the signiﬁcance of chimerism mea-
surements over time as a prognostic factor for DFS and/or OS.
To account for the association between chimerism and event
time, we performed analyses based on “shared random ef-
fects” models [10-12], wherein patient-speciﬁc random ef-
fects are included in both the mean of the longitudinal
chimerism process and the linear predictor in the hazard
function of the event time model.Table 1
Characteristics of Patients Who Achieved CR after Allo-SCT (n ¼ 195)
Variable Value Number (%)
Gender Male 104 (53.3)
Female 91 (46.7)
Age, yr >50 72 (36.9)
50 123 (63.1)
Disease AML 157 (80.5)
MDS 38 (19.5)
Disease status at
transplantation
CR 112 (57.4)
Active disease 83 (43.6)
Cytogenetics Good 18 (9.2)
Intermediate 102 (52.3)
Poor 74 (37.9)
Unknown 1 (.5)
Donor type MRD 98 (50.2)
MUD 78 (40.0)
Mismatched 19 (9.7)
Stem cell source Bone Marrow 87 (44.6)
Peripheral Blood 108 (55.4)
MRD indicates matched related donor; MUD, matched unrelated donor.METHODS
Patient Selection
We studied 206 patients with AML (n ¼ 165) or MDS (n ¼ 41) trans-
planted at The University of Texas M.D. Anderson Cancer Center between
April 2001 and October 2007. All protocols, including this retrospective
analysis, were approved by the institutional review board of the University
of Texas M.D. Anderson Cancer Center Patients provided written informed
consent for their treatment and were treated in accordance with the
Declaration of Helsinki.
All preparative regimens included i.v. busulfan and ﬂudarabine at a
myeloablative dose intensity [19,20]. Of the 206 patients, 51% of patients
(n ¼ 105) had received matched related donor transplants, 40% (n ¼ 82)
receivedmatched unrelated donor transplants, and 9% (n¼ 19) received a 1-
antigen-mismatched transplant. Antithymocyte globulin was administered
to patients who received grafts from matched unrelated donor or mis-
matched grafts [19,20]. All patients received tacrolimus and minidose
methotrexate for graft-versus-host disease (GVHD) prophylaxis.
Cytogenetic risk categories were deﬁned as follows: favorable-risk cy-
togenetics included patients with translocation (t)(8;21); inversion (inv)(16)
or t(16;16); or t(15;17). Adverse-risk cytogenetics included patients with a
complex karyotype (4 abnormalities); inv(3) or t(3;3); t(6;11); del (5q); del7q; 11q23 abnormalities excluding t(9;11) and t(11;19). Intermediate-risk
cytogenetics were deﬁned as patients with a normal karyotype, as well as
those who did not ﬁt the criteria for favorable- or adverse-risk cytogenetics
[21,22].
DNA chimerism in blood and bone marrow was measured using PCR-
based technology, as previously described [20]. Brieﬂy, DNA microsatellite
polymorphisms were analyzed by PCR using standard primers followed by
analysis using GeneScan software (Applied Biosystems, Foster City, CA).
Percent chimerismwas calculated using the fraction of donor to total DNA in
the analyzed sample.
Statistical Methods
Frequencies and percentages were used to summarize patient charac-
teristics. OS and DFSwere recorded from the time of allo-SCT. Unadjusted OS
and DFS distributions were estimated using themethod of Kaplan andMeier
[23]. To assess the association between chimerism measured at 1 or more of
days 30, 60, and 90 after allo-SCT and OS or DFS, a joint model for the lon-
gitudinal chimerism process and the event time distribution [10-12] was ﬁt.
This was done (1) for the longitudinal process of complete (100%) T cell
chimerism and event time (OS or DFS) and (2) for the longitudinal process of
percent T cell chimerism and event time. In each joint model, to account for
the association between chimerism and event time, 1 or more random
patient-speciﬁc parameters were included in both the linear term of the
mean chimerism process and the hazard function of the event time. Details
are given in Supplemental Methods. Computations for all statistical analyses
were conducted in R (version 2.14.1; R Development Core Team) and SAS
(version 9.2; SAS Institute Inc., Cary, NC).
RESULTS
Patient Characteristics
TwohundredsixpatientswitheitherAML (n¼165)orMDS
(n ¼ 41) received allo-SCT between April 2001 and October
2007. The median age at time of transplant was 47 years; 83
patients (40%) were older than 50 years. Ninety-eight patients
(48%) were women, and 108 (52%) were men. One hundred
ninety-ﬁve patients achieved CR after allo-SCT and were used
in the chimerism analysis.We focused our chimerism analysis
on this subgroup of patients because patients who fail to
achieve CR by deﬁnition have a mixed chimera and worse
outcomes and therefore intrinsically bias the effect of chime-
rism on OS and DFS. Pretransplant patient characteristics for
this subgroup of patients are presented in Table 1.
CR was deﬁned as the achievement of a normalized
marrowmaturation proﬁle and less than 5% blasts (cytologic
CR). Specialized data regarding the assessment of minimal
residual disease such as ﬂow cytometry, ﬂuorescence in situ
hybridization, or cytogenetics were not included; also, strict
peripheral blood criteria for CR, such as platelets > 100,000
or absolute neutrophil count  1500, were not applied [24].
Figure 1. Survival curves of OS (A) and DFS (B). Kaplan-Meier plots showing OS and DFS for patients who achieved CR after allo-SCT (n ¼ 195). Dashed lines indicate
95% conﬁdence intervals.
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The median follow-up period for all patients and those
who achieved CR after allo-SCT was 28.2 months (range, .8 to
104.6 months) and 31 months (range, 1.1 to 105 months),
respectively. The 2-year OS rates for all patients and those
who achieved CR after allo-SCT were 54% and 57%, respec-
tively. The 2-year DFS rates for all patients and those who
achieved CR after allo-SCT were 47% and 50%, respectively.
Kaplan-Meier plots of OS and DFS distributions for patients
who achieved CR after allo-SCT are shown in Figure 1.
Transplant Outcomes for Patients Who Achieved CR after
Allo-SCT
Engraftment was achieved in all patients who achieved
CR after allo-SCT (n¼ 195). Therewere no deaths reported by
day 30. One hundrededay mortality for this subgroup of
patients was 3% (n ¼ 5) and was caused by recurrent disease
(n ¼ 3), graft failure (n ¼ 1), and acute GVHD (n ¼ 1). Thirty-
three percent of patients (n ¼ 65) developed grades II to IV
acute GVHD, 9% (n ¼ 18) developed grades III to IV acute
GVHD, and 53% (n ¼ 104) developed chronic GVHD.
Individual Chimerism Measurement Effects on OS or DFS
Table 2 summarizes landmark Cox model analyses [9] of
the effects of day 30, 60, and 90 chimerism and OS or DFS.
Each ﬁtted model evaluates the effect of 1 post-SCT chime-
rism measurement, with times to recurrence or death
recorded from the day chimerism was evaluated. The ﬁttedTable 2
Fitted Landmark Cox Models for OS or DFS as a Function of Percent Donor Chimer
OS
Na Nc Coef (95% CI) P
Percent donor T cells
Day
30 195 121 .007 (.019, .005) .230
60 193 103 .008 (.022, .006) .220
90 187 114 .007 (.019, .005) .290
Percent donor myeloid cells
Day
30 195 123 .006 (.053, .065) .850
60 193 101 .009 (.031, .013) .390
90 187 113 .056 (.076, .036) <.001
In each model, the event time was recorded from the day chimerism was measured
a beneﬁcial effect. Na indicates number of subjects alive at the given day; Nc, num
efﬁcient; CI, conﬁdence interval.models indicate that a higher fraction of donor myeloid cells
at day 90 had a beneﬁcial effect on both OS and DFS, whereas
a higher fraction of donor myeloid or T cells at day 60 had a
beneﬁcial effect on DFS but not OS.
Inferences from Joint Models of Longitudinal Chimerism
Processes and OS or DFS
Among the 206 patients, 154 (75%) achieved complete
(100%) donor T cell chimerism and 162 (79%) achieved
complete donor myeloid cell chimerism. Although interval
censoring of the times complicates estimation, the median
time to complete T cell chimerism was between 1 and
2 months and the median time to complete myeloid
chimerism was less than 1 month.
The ﬁtted joint longitudinal-event time models use each
patient’s entire chimerism process over time (Figure 2).
Because longitudinal indicators of complete donor chime-
rism in this dataset were nearly identical in each patient for
T cells and myeloid cells, an indicator of cell type cannot be
included in the joint model of probability of complete (100%)
donor T cell chimerism after allo-SCT and OS (Table 3).
Because the T cell and myeloid donor cell percentages
differed among patients with incomplete chimerism, an in-
dicator for cell type was included in the ﬁtted joint model for
the longitudinal percent donor T cells or myeloid cells after
allo-SCT and OS (Table 4).
The ﬁtted joint model for probability of complete donor
T cell chimerism after allo-SCT and OS (Table 3) showed thatism at Day 30, 60, or 90
DFS
Na Nc Coef (95% CI) P
195 121 .012 (.022, .002) .027
187 102 .022 (.036, .008) <.001
172 110 .003 (.017, .011) .620
195 123 .025 (.090, .040) .450
187 100 .058 (.099, .017) .007
172 113 .063 (.096, .030) <.001
. A negative coefﬁcient estimate corresponds to a lower event rate and hence
ber of subjects alive with chimerism evaluated at the given day; Coef, Co-
Figure 2. Longitudinal measurements of T cell and myeloid chimerism. Plots of longitudinal T cell (A) and myeloid cell (B) chimerism measurements for patients who
achieved CR after allo-SCT (n ¼ 195).
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and a higher complete chimerism probability was signiﬁ-
cantly associated with longer OS (P ¼ .017). A similar joint
model for complete donor T cell chimerismwith DFS in place
of OS (Supplemental Table 1) gave similar results and the
same substantive conclusions.
The ﬁtted joint model for percent of donor T cells or
myeloid cells after allo-SCT and OS (Table 4) showed that
increasing donor cell chimerism was signiﬁcantly associated
with better OS (P ¼ .027), whereas decreasing donor cell
chimerismwas highly signiﬁcantly associated with worse OS
(P < .001). A similar joint model for percent of donor cells
with DFS in place of OS (Supplemental Table 2) also showed
that a decreasing percent of donor cells was signiﬁcantly
associated with worse DFS (P ¼ .019), but an increasingTable 3
Fitted Joint Model for Longitudinal Complete (100%) T Cell Chimerism In-
dicator and OS for Patients Who Achieved CR after Allo-SCT (n ¼ 195)
Coefﬁcient SE P 95% CI
Longitudinal model for complete donor T cell chimerism*
Time after allo-SCT .146 .027 <.001 .093, .199
Disease status at time of
allo-SCT
CR vs. active .799 .529 .135 .238, 1.836
Allotype
MRD vs. MUD .380 .836 .650 1.259, 2.019
Mismatched vs. MUD .253 .558 .651 1.347, .841
Cytogenetic risk group
Good vs. poor .066 .476 .890 .867, 1.000
Intermediate vs. poor .186 .833 .824 1.447, 1.819
Cox model for OS timey
Shared random effect .164 .068 .017 .297, .031
Disease status at time of
allo-SCT
CR vs. active 1.151 .238 <.001 1.617, .685
Allotype
MRD vs. MUD .465 .256 .071 .967, .037
Mismatched vs. MUD .302 .318 .342 .321, .925
Cytogenetic risk group
Good vs. poor .318 .361 .381 1.026, .390
Intermediate vs. poor .452 .237 .058 .916, .014
SE indicates standard error; CI, conﬁdence interval; MUD, matched unre-
lated donor; MRD, matched related donor.
* A positive (negative) coefﬁcient estimate in the longitudinal model
corresponds to higher (lower) probability of complete T cell chimerism.
y A positive (negative) coefﬁcient estimate in the Cox model corresponds
to a higher (lower) risk of death and thus on average a shorter (longer) OS
time.percent of donor cells was not signiﬁcantly associated with
DFS (P ¼ .379).
Table 5 applies the ﬁtted joint model in Table 4 by giving
predicted 1-year OS and DFS probabilities for particular
combinations of baseline covariates and percent of T cell or
myeloid cell chimerism at days 30 and 90. The strongest
message in Table 5 is that patients showing an increase from
95% chimerism at day 30 to 100% chimerism at day 90 had
the highest 1-year OS probabilities. Table 5 also illustrates
the well-known beneﬁcial effects of CR, good cytogenetics,
and a matched related donor.
To interpret Table 5, for example, focusing on patients
transplanted inCRwith amatched related donor allograft and
good cytogenetics, if percent donor chimerism increased
from 95% on day 30 to 100% on day 90, labeled “95, 100”,
one may infer that OS at 1 year was 95% (95% conﬁdence in-
terval [CI], 92% - 100%). In contrast, if chimerism decreased
from 95% at day 30 to 90% at day 90, labeled “95, 90”, then
OS at 1 year was 72% (95% CI, 62% - 84%) for these patients.
This effect was much more pronounced for patients trans-
planted with active disease and poor cytogenetics who
received a matched unrelated donor allograft, with 1 year OS
of 83% (95% CI, 65% - 100%) if chimerism increased from95% at
day 30 to 100% at day 90, labeled “95,100”, compared to 30% 1
yearOS (95%CI,18% - 50%) if the percent chimerismdecreased
from 95% at day 30 to 90% at day 90, labeled “95, 90”.DISCUSSION
Establishment of donor cell chimerism provides useful
information regarding the prognosis of AML/MDS patients
after allo-SCT. Although the importance of chimerism status
after allo-SCT in leukemia has been validated and compared
with other methods of measuring minimal residual disease,
studies have used absolute chimerism values and qualitative
criteria of chimerism changes to determine its role as a
prognosticator [7,15,25]. In this study of 195 patients with
AML or MDS in CR, we showed that longitudinal chimerism
measurements are highly predictive of both OS time and DFS
time after allo-SCT. The ﬁtted joint models showed that
increasing percent donor chimerism was beneﬁcial while
decreasing percent donor chimerismwas harmful for overall
survival in these patients.
Our results are supported by 2 other studies that have
shown a beneﬁt in following chimerism over time. In a study
of 101 pediatric patients with ALL, Bader et al. [6] reported
Table 4
Fitted Joint Model for Longitudinal Chimerism Percentage and OS for Pa-
tients Who Achieved CR after Allo-SCT (n ¼ 195)
Coefﬁcient SE P 95% CI
Longitudinal model for T cell or myeloid cell percent donor cells*
Type of chimerism
Myeloid vs. T celly 8.641 .861 <.001 6.953, 10.329
Time after allo-SCT .378 .418 .366 1.197, .441
Disease status at time of
allo-SCT
CR vs. active 3.448 1.949 .079 .372, 7.268
Allotype
MRD vs. MUD 4.171 2.063 .045 8.214, .128
Mismatched vs. MUD 1.709 3.267 .602 8.112, 4.694
Cytogenetic risk group
Good vs. poor 1.494 2.079 .474 2.581, 5.569
Intermediate vs. poor 2.795 3.517 .428 4.098, 9.688
Cox model for OS timez
Shared random effects
Increasing donor
chimerism
.479 .217 .027 .904, .053
Decreasing donor
chimerism
.166 .047 <.001 .074, .258
Disease status at time of
allo-SCT
CR vs. Active .884 .208 <.001 1.292, .476
Allotype
MRD vs. MUD .026 .240 .912 .496, .444
Mismatched vs. MUD .174 .318 .583 .449, .797
Cytogenetic risk group
Good vs. poor .390 .223 .081 .827, .047
Intermediate vs. poor .780 .411 .057 1.585, .026
SE indicates standard error; CI, conﬁdence interval; MUD, matched unre-
lated donor; MRD, matched related donor.
* A positive (negative) coefﬁcient estimate in the longitudinal model
corresponds to higher (lower) percent donor cells.
y Indicates that the percentage of myeloid cell chimerism is signiﬁcantly
higher than T cell chimerism.
z A positive (negative) coefﬁcient estimate in the Cox model corresponds
to a higher (lower) risk of death and thus on average a shorter (longer) OS
time.
X. Tang et al. / Biol Blood Marrow Transplant 20 (2014) 1139e1144 1143higher 3-year DFS rates in patients with complete
chimerism/low-level mixed chimerism (DFS ¼ 66%) and
increasing donor cell chimerism (DFS ¼ 66%), in contrast
with patients who had decreasing donor cell chimerism
(DFS ¼ 23%; P < .0001), which was deﬁned as >5% increase
in the proportion of host-derived cells between 2 consecu-
tive chimerism assessments at predeﬁned time points.
Eighty-ﬁve percent of patients received total body irradi-
ationebased preparative regimens and 41% received
T celledepleted stem cell grafts. Similar to childhood ALL, in
another study of 81 pediatric patients with AML, decreasing
donor cell chimerismwas also shown to be a poor prognosticTable 5
Predicted 1-Year OS and DFS Probabilities for 9 Combinations Obtained from 3 Sp
Chimerism Values at Days 30 and 90
Patient Characteristics % Chimerism at
Days (30, 90)
Pre
OS
P
Complete remission 95, 95 .78
Allotype ¼ MRD 95, 100 .94
Cytogenetics ¼ good 95, 90 .71
Active disease 95, 95 .40
Allotype ¼ MUD 95, 100 .82
Cytogenetics ¼ poor 95, 90 .29
Active disease 95, 95 .84
Allotype ¼ MRD 95, 100 .91
Cytogenetics ¼ intermediate 95, 90 .58
CI indicates conﬁdence interval; MUD, matched unrelated donor; MRD, matched r
Predicted values are based on the ﬁtted joint models for percentage of T cell or mindicator [7]. In this study, 59% probability of 3-year DFS was
shown for patients with complete chimerism/low-level
mixed chimerism, 60% for patients with increasing donor
cell chimerism, and 28% for patients with decreasing donor
cell chimerism (P < .005). Eighty-eight percent of patients in
the study received busulfan-based conditioning regimen
and 40% received Tcelledepleted stem cell grafts. The results
from this study were corroborated in a prospective multi-
center trial that conﬁrmed the clinical signiﬁcance of
chimerism as a prognostic indicator in childhood AML [15].
All 3 studies used a semiquantitative PCR approach based on
the ampliﬁcation of short tandem repeat markers to mea-
sure chimerism [26]. Furthermore, in these 3 studies early
immunotherapeutic intervention based on chimerism re-
sults was advocated to improve outcome (ie, prevent clinical
relapse).
Other studies, however, have questioned the value of
chimerism in prognosticating disease outcomes. In a retro-
spective study of 89 patients with ALL who received allo-SCT,
achievement of <90% and 90% donor CD3þ T cells was
associated with a nonsigniﬁcant difference in 3-year actu-
arial DFS probability (62% versus 48%; P ¼ .49) [16]. Patients
enrolled in that study had received total body irradi-
ationebased preparative regimens, and chimerism analyses
were performed at a median of 77 days (range, 65 to
113 days) after transplantation using conventional cytoge-
netic analysis and ﬂuorescence in situ hybridization for sex
mismatched donors and molecular methodology for same
sex donors. Another study by Mossallam et al. [17] that
included 673 patients with a variety of malignancies,
including MDS/AML (n ¼ 380), ALL (n ¼ 111), chronic lym-
phocytic leukemia (n ¼ 118), and other malignancies
(n ¼ 64), and who received a wide variety of preparative
regimens showed a lack of correlation between chimerism
and survival outcomes after allo-SCT. Speciﬁcally, there were
no signiﬁcant correlations between donor chimerism and
overall mortality or relapse. Chimerism was measured using
ﬂuorescence in situ hybridization for sex-mismatched do-
nors and molecular techniques for same-sex donors.
A principal factor that may have caused the conﬂicting
results in the aforementioned studies is the relative hetero-
geneity in the patient populations that were investigated in
each study, the preparative regimens used, and the different
methods used to measure chimerism. Our analysis here is
homogeneous and was conducted in adult patients with only
a diagnosis of AML/MDS and having received the same
myeloablative, reduced-toxicity conditioning regimen of i.v.
busulfan/ﬂudarabine followed by infusion of allogeneic stemeciﬁc Combinations of Patient Prognostic Covariates and 3 Pairs of Percent
dicted Probabilities at 1 Year Post-SCT
DFS
95% CI P 95% CI
0 .689, .884 .737 .643, .845
9 .918, 1.000 .638 .459, .887
8 .616, .836 .615 .478, .792
2 .269, .601 .412 .287, .593
6 .648, 1.000 .272 .083, .895
6 .176, .498 .244 .113, .529
2 .724, .978 .687 .505, .935
8 .816, 1.000 .576 .326, 1.000
1 .367, .918 .550 .322, .940
elated donor.
yeloid cell chimerism and OS or DFS summarized in Table 3.
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standard molecular PCR-based methodology to analyze
chimerism in all patients. Furthermore, our results empha-
size the value of the rate of change of chimerism as being the
most important factor in predicting outcomes, not the
chimerism status or absolute value at individual time points.
This observation is very important because it highlights the
signiﬁcance of the evolution of the donor graft over time,
which can change independently of the underlying disease
because of exposure to a variety of factors that affect the
immune system. On the other hand, the change in the per-
centage of donor cells over time may be a direct function of
disease relapse and in turn could decrease the ability of the
donor graft to control the underlying malignancy. Further-
more, because malignant cells likely have a higher prolifer-
ative rate in comparison with normal hematopoietic stem
cells, a slowly decreasing mixed chimerism may reﬂect
proliferation of host-derived normal hematopoietic cells
rather than AML.
In conclusion, we show that serial chimerism measure-
ment is a valuable tool in prognosticating survival outcomes
in patients with AML/MDS after allo-SCT. Our results high-
light the value of the rate of change in chimerism rather than
the absolute percentage of chimerism or chimerism status in
predicting survival after allo-SCT in patients receiving mye-
loablative i.v. busulfan/ﬂudarabine and who achieve CR after
allo-SCT for AML/MDS.
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